MedPath

HR20013 Shows Non-Inferiority in Preventing Chemotherapy-Induced Nausea and Vomiting

• A recent study, HR20013, has demonstrated non-inferiority compared to standard antiemetic therapy in preventing chemotherapy-induced nausea and vomiting (CINV). • The PROFIT study assessed the efficacy and safety of HR20013, providing evidence for its potential as an alternative treatment option for CINV. • The findings suggest that HR20013 could offer a comparable level of protection against CINV, potentially expanding the available options for patients undergoing chemotherapy. • Further research may explore HR20013's specific advantages or suitability for certain patient subgroups experiencing CINV.

A new study, known as PROFIT (HR20013), indicates that HR20013 is non-inferior to current standard treatments in preventing chemotherapy-induced nausea and vomiting (CINV). This finding suggests a potential new option for managing this common and distressing side effect of cancer treatment. The study provides evidence supporting HR20013 as a viable alternative for patients undergoing chemotherapy.
The PROFIT study was designed to evaluate the effectiveness and safety of HR20013 in preventing CINV. Chemotherapy often leads to nausea and vomiting, significantly impacting patients' quality of life and adherence to treatment regimens. Effective antiemetic strategies are therefore crucial in cancer care. The results of this study suggest that HR20013 offers a comparable level of protection against CINV, potentially broadening the range of available options for patients.
Further investigations could explore the specific benefits of HR20013 or its suitability for particular patient populations experiencing CINV. Understanding its unique properties may allow for more personalized and effective management of CINV in cancer patients.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

TenNor's Rifasutenizol Achieves High Eradication Rate in Phase III H. pylori Trial

TenNor Therapeutics' rifasutenizol triple therapy achieved a >90% eradication rate in treating Helicobacter pylori (H. pylori) infection in a Phase III trial.
The rifasutenizol regimen outperformed the current standard of care, bismuth-containing quadruple therapy (BQT), in H. pylori eradication.

Triplet Antiemetic Therapy Shows Promise in Preventing Chemotherapy-Induced Nausea and Vomiting

A phase II trial evaluated the efficacy and safety of triplet antiemetic therapy (palonosetron, aprepitant, and olanzapine) in breast cancer patients undergoing highly emetogenic chemotherapy (HEC).
The study demonstrated a total control (TC) rate of nausea and vomiting in the overall phase (0-120 hours post-chemotherapy), suggesting the effectiveness of the triplet therapy.

Olanzapine and Cannabis Extracts Show Promise in Managing Chemotherapy-Induced Nausea

A study at ASCO found olanzapine significantly reduces severe nausea in breast cancer patients undergoing chemotherapy, especially when standard antiemetics are insufficient.
Research published in the Journal of Clinical Oncology indicates that a cannabis extract with THC/CBD effectively reduces nausea and vomiting during chemotherapy.

Phase 3 ASCEND Trial Shows Long-Term Safety of STS101 Nasal Powder for Acute Migraine Treatment

Phase 3 ASCEND study demonstrates the long-term safety and tolerability of STS101 (dihydroergotamine nasal powder) over 12-18 months for acute migraine treatment.
The study involved 344 adults who self-administered STS101 as needed, with a low incidence of treatment-emergent adverse events, mainly mild to moderate nasal discomfort.

Theriva Biologics' SYN-004 Shows Positive Safety Profile in Phase 1b/2a Trial for aGVHD Prevention

The Data and Safety Monitoring Committee (DSMC) has recommended advancing Theriva Biologics' SYN-004 trial to Cohort 3 after reviewing Cohort 2 data.
SYN-004 demonstrated a favorable safety profile in allogeneic hematopoietic cell transplant (HCT) recipients, with adverse events typical for this patient population.

Crofelemer Shows Promise in Breast Cancer Subgroup for Diarrhea Management

Jaguar Health's crofelemer demonstrated statistically significant benefits in a prespecified subgroup of breast cancer patients experiencing diarrhea during cancer therapy.
The Phase III OnTarget trial data suggests crofelemer could improve adherence to cancer treatments by managing diarrhea, a common side effect of chemotherapy, immunotherapy, and targeted therapies.

NRG Oncology Trial: Radiotherapy and Cisplatin Remain Standard of Care for p16+ Oropharyngeal Cancer

The NRG-HN005 phase II/III trial found that de-intensified treatment arms were inferior to standard radiotherapy and cisplatin for p16+ oropharyngeal cancer.
The control arm, using standard chemoradiation, demonstrated a 98.1% 2-year progression-free survival rate, setting a high benchmark for future studies.

NUBEQA® (darolutamide) Plus ADT Significantly Improves Outcomes in Metastatic Hormone-Sensitive Prostate Cancer

The Phase III ARANOTE trial demonstrated that NUBEQA® (darolutamide) plus androgen deprivation therapy (ADT) significantly improved radiological progression-free survival (rPFS).
The trial showed a 46% statistically significant reduction in the risk of progression or death compared to placebo plus ADT (HR 0.54; 95% CI 0.41-0.71; P<0.0001).

De-escalated Therapy Shows Excellent Survival in HR+/HER2+ Breast Cancer

Patients with HR+/HER2+ early breast cancer achieved excellent survival outcomes with neoadjuvant endocrine therapy or chemotherapy plus trastuzumab and pertuzumab.
Achieving pathological complete response (pCR) was associated with significantly improved event-free survival and overall survival in the WSG-TP II trial.

5-FU Bolus Omission Reduces Toxicity in Advanced GI Cancer Chemotherapy

A recent study involving over 11,000 patients suggests that omitting the 5-FU bolus in multidrug chemotherapy regimens for advanced gastrointestinal cancers can reduce side effects.
The omission of the 5-FU bolus did not compromise overall survival in patients with colorectal, pancreatic, or gastroesophageal malignancies.

Reference News

[1]
HR20013 Demonstrates Noninferiority in Preventing Chemo-Induced Nausea, Vomiting
docwirenews.com · Sep 8, 2024

© 2024 Mashup Media, LLC. All rights reserved.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy